ClinicalTrials.gg
CompletedNCT00136903Updated Jan 31, 2022

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

A Phase 2 interventional study of Prochymal® - 2 Million cells/kg and Prochymal®- 8 Million cells/kg in Graft Vs Host Disease, sponsored by Mesoblast, Inc.. Completed at 9 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-01-31.

Sponsored by Mesoblast, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2006, 20 years 3 months ago, and no results have been posted to the registry.
  • Registered 3 months after the study started (first participant enrolled Apr 2005, registered Aug 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
181st of 389
32 · median 30
Started
2005
with 13 others
Phase 2
164 of 454
15 open now
Registered
80th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 181st largest by enrollment of the 389 interventional ones that give a count, is one of 14 that started in 2005, is one of 164 in phase 2, and was the 80th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

To establish the safety and efficacy of two dose levels of ex-vivo cultured adult human mesenchymal stem cells (hMSCs) (Prochymal®) in participants experiencing acute GVHD, Grades II-IV, post hematopoietic stem cells (HSC) transplant.

Read the detailed description

Protocol 260 - Participants will be randomized with equal probability to the treatment arms (2 million cells/kilogram (kg) of Prochymal® or 8 million cells/kg of Prochymal®) using a stratified block design. The stratification factor is acute GVHD grade. For the purpose of stratification, the GVHD grades are II and III-IV. Treatment with investigational agent will be administered on study Days 1 and 4. Participants will be followed for safety and efficacy until Day 28 after initiation of treatment with the investigational agent, or until withdrawal or death, whichever occurs first.

Protocol 261- This study is designed as a long-term safety follow-up of participants who take part in the preceding clinical study of Prochymal® (Protocol 260) for the treatment of acute GVHD. Participants will be enrolled in Study 261 upon completion of the preceding Study 260.

03

Conditions studied

  • Graft Vs Host Disease

Keywords

  • Graft vs Host Disease
  • (GVHD)
  • Graft Versus Host Disease
  • Bone marrow transplant
  • Stem cells
  • Mesenchymal stem cells (MSCs)
  • Adult stem cells
  • Leukemia
  • Lymphoma
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Protocol 260 Inclusion Criteria:

  • Participant must be 18 to 70 years of age inclusive.
  • If female and of child-bearing age, participant must be non-pregnant, not breast feeding, and use adequate . Males must use adequate contraception.
  • Participant must have newly diagnosed, Grade II-IV acute requiring therapy. for confirmation of GVHD is not mandatory, but is recommended when feasible. Enrollment should not be delayed awaiting biopsy results.
  • Participant must have received either full or reduced intensity myeloablative regimens followed by an hematopoietic stem cell transplant using bone marrow, peripheral blood stem cell, or cord blood, including donor lymphocyte infusion (DLI).
  • Participant must have minimal renal and hepatic function as defined by:

    * Calculated (CLcr) of > 30 mL/min using the Cockroft-Gault equation.

  • Participant must be available for all specified assessments at the study site through study Day 28.
  • Participant must provide written and authorization for use and disclosure of protected health information (PHI).

Protocol 260 Exclusion Criteria:

  • Participant has received previous treatment for Grade II-IV acute GVHD (except as noted in Criterion 2).
  • Participant has been treated for GVHD with methylprednisolone, > 2mg/kg/day, for more than 72 hours prior to receiving Prochymal®.
  • Participant has uncontrolled alcohol or substance abuse within 6 months of randomization.
  • Participant has received an agent (not approved by food and drug administration (FDA) for marketed use in any indication) within 30 days of randomization. Participant may not receive an investigational agent during the 28-day study period.
  • Participant has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the participant (e.g., uncontrolled infection, right heart failure, pulmonary hypertension, etc.).
  • Participant has unstable arrhythmia.
  • Participant is unwilling to sign consent form for the long-term follow-up study, Protocol 261.
  • Participant has a known allergy to bovine or porcine products.
  • Participant had received transplant for a solid tumor disease.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Active comparator
    Prochymal® - 2 Million cells/kg

    Participants will receive Prochymal® consisting of 2 million hMSCs/kg actual body weight, intravenously (IV) on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 milligrams (mg)/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.

    Drug: Prochymal® - 2 Million cells/kg · Drug: Methylprednisolone · Drug: Prednisone · Drug: Cyclosporine · Drug: Tacrolimus · Drug: Mycophenolate Mofetil

  • Active comparator
    Prochymal® - 8 Million cells/kg

    Participants will receive Prochymal® consisting of 8 million hMSCs/kg actual body weight IV on Days 1 and 4 along with daily standard of care which includes methylprednisolone 2 mg/kg IV or prednisone 2.5 mg/kg orally. Participants will also continue cyclosporine, tacrolimus, and/or mycophenolate mofetil (MMF) at full therapeutic doses.

    Drug: Prochymal®- 8 Million cells/kg · Drug: Methylprednisolone · Drug: Prednisone · Drug: Cyclosporine · Drug: Tacrolimus · Drug: Mycophenolate Mofetil

Interventions

  • DrugProchymal® - 2 Million cells/kg

    Drug page: Remestemcel-l

    2 million hMSCs/kg actual body weight, IV on study Days 1 and 4

    Also known as: Remestemcel-L, ex-vivo cultured adult human mesenchymal stem cells, hMSCs

  • DrugProchymal®- 8 Million cells/kg

    Drug page: Remestemcel-l

    8 million hMSCs/kg actual body weight IV on study Days 1 and 4

    Also known as: Remestemcel-L, ex-vivo cultured adult human mesenchymal stem cells, hMSCs

  • Methylprednisolone 2 mg/kg administered intravenously.

  • Prednisone 2.5 mg/kg administered orally.

  • Administered as prescribed by the caregiver.

  • Administered as prescribed by the caregiver.

  • Administered as prescribed by the caregiver.

06

What researchers measure

Primary outcomes

  1. Protocol 260 - Response by Day 28, also called Overall Response (OR). OR includes complete response (CR) and partial response (PR)

    Time frame: 28 Days

  2. Protocol 261-The incidence rate of different adverse events among participants treated with either dose of Prochymal® in the preceding study (Protocol No. 260).

    Time frame: 2 Years

Secondary outcomes

  1. Protocol 260 - Partial Response or Improvement of GVHD by Day 28 in one or more organs involved with GVHD symptoms at Day 1,

    Time frame: 28 Days

  2. Protocol 260 - Time to best response of GVHD

    Time frame: 28 Days

  3. Protocol 260 - Time to improvement of GVHD in one or more organs

    Time frame: 28 Days

  4. Protocol 261 - Survival through study day 90

    Time frame: 90 Days

07

Study locations

9 sites
  • St. Francis Hospital
    Indianapolis, Indiana 46237, United States
  • Kansas City Cancer Centers - BMT
    Kansas City, Missouri 64111, United States
  • The Cancer Center at Hackensack University
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Mt. Sinai Hospital
    New York, New York 10029, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • New York Medical College
    Valhalla, New York 10595, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Medical College of Wisconsin, FEC
    Milwaukee, Wisconsin 53226, United States
08

References and documents

Publications

  • Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol. 2002 Jan;30(1):42-8. doi: 10.1016/s0301-472x(01)00769-x. PubMed 11823036 ↗
  • Deans RJ, Moseley AB. Mesenchymal stem cells: biology and potential clinical uses. Exp Hematol. 2000 Aug;28(8):875-84. doi: 10.1016/s0301-472x(00)00482-3. PubMed 10989188 ↗
  • Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant. 2005 May;11(5):389-98. doi: 10.1016/j.bbmt.2005.02.001. PubMed 15846293 ↗
  • Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004 May 1;363(9419):1439-41. doi: 10.1016/S0140-6736(04)16104-7. PubMed 15121408 ↗
  • Le Blanc K, Pittenger M. Mesenchymal stem cells: progress toward promise. Cytotherapy. 2005;7(1):36-45. doi: 10.1080/14653240510018118. PubMed 16040382 ↗
  • Kebriaei P, Isola L, Bahceci E, Holland K, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Monroy R, Uberti J. Adult human mesenchymal stem cells added to corticosteroid therapy for the treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant. 2009 Jul;15(7):804-11. doi: 10.1016/j.bbmt.2008.03.012. PubMed 19539211 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2005 to primary completion in Jul 2006, 15 months.

Of 102 phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 87. This study's 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2005
First posted
Aug 29, 2005
StartActual
Apr 27, 2005
Primary completionActual
Jul 28, 2006
CompletionActual
Jul 14, 2008
Last update
Jan 31, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00136903
Lead sponsor
Mesoblast, Inc.
Responsible party
Sponsor
First posted
Aug 29, 2005
Start date
Apr 27, 2005
Primary completion
Jul 28, 2006
Completion
Jul 14, 2008
Last update
Jan 31, 2022

Study contacts

Christopher James, PA
study director · Mesoblast, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remestemcel-l

Start the discussion